Results 21 to 30 of about 3,744 (163)

Enfermedad tromboembólica venosa en obstetricia

open access: yesRevista Ciencias Biomédicas, 2020
Introducción: la Enfermedad Tromboembólica Venosa (ETV) incluyen: trombosis venosa superficial, venosa profunda, de las venas ováricas, pélvica séptica y el trombo embolismo pulmonar.
Édgar Rivas Perdomo   +1 more
doaj   +1 more source

Right heart thrombi (RHT) and clot in transit with concomitant PE management: Approach and considerations

open access: yesPulmonary Circulation, Volume 12, Issue 2, April 2022., 2022
Abstract Right heart thrombi (RHT) continues to pose a clinical dilemma for multiple specialties and is especially concerning when present with concomitant pulmonary embolism (PE). Patients with PE and RHT are at an increased risk of poor outcomes compared to PE without RHT. Although the exact incidence of RHT is unknown, the increasing use of point‐of‐
Akhil Khosla   +5 more
wiley   +1 more source

International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis

open access: yesJournal of Thrombosis and Haemostasis, Volume 19, Issue 4, Page 1123-1129, April 2021., 2021
Abstract Pediatric thromboembolism is a rare and heterogenous disease. As a result, there is a paucity of knowledge with regard to natural history, management, and outcomes of most types of pediatric venous and arterial thromboembolism. International research collaboration is needed to fill these knowledge gaps.
C. Heleen van Ommen   +17 more
wiley   +1 more source

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 3, Page 426-438, March 2021., 2021
Abstract Background The XALIA and XALIA‐LEA prospective, noninterventional studies investigated the safety and effectiveness of rivaroxaban versus standard anticoagulation for venous thromboembolism (VTE) treatment in routine clinical practice across global regions.
Sylvia Haas   +10 more
wiley   +1 more source

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 2, Page 326-341, February 2021., 2021
Abstract Introduction Venous thromboembolism (VTE) has a long‐term risk of recurrence, dependent on the presence or absence of provoking risk factors at the time of the event. Objective To compare clinical characteristics, anticoagulant patterns, and 12‐month outcomes in patients with transient provoking factors, active cancer, and unprovoked VTE ...
Walter Ageno   +14 more
wiley   +1 more source

Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

open access: yesResearch and Practice in Thrombosis and Haemostasis, Volume 5, Issue 1, Page 168-178, January 2021., 2021
Abstract Background The optimal therapy of patients with acute subsegmental pulmonary embolism (PE) is controversial. Methods We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the rate of symptomatic PE recurrences during anticoagulation in patients with subsegmental, segmental, or more central PEs.
Carmen Fernández‐Capitán   +161 more
wiley   +1 more source

Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

open access: yesClinical and Translational Science, Volume 14, Issue 1, Page 335-342, January 2021., 2021
Edoxaban is used for venous thromboembolism (VTE) treatment. Real‐life data are lacking about its use in long‐term therapy. We aimed to assess the efficacy and the safety of edoxaban for long‐term VTE treatment in a real‐life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban
Giuseppe Camporese   +10 more
wiley   +1 more source

Tromboembolismo pulmonar agudo en tiempos de SARS-CoV-2: diagnóstico y tratamiento

open access: yesArchivos de Cardiología de México, 2021
Existe una clara relación entre la infección por el nuevo coronavirus 2 y el diagnóstico de enfermedad tromboembólica venosa, como consecuencia del desarrollo de un síndrome de respuesta inflamatoria sistémica debido a la activación de la cascada de la ...
Cristhian E. Scatularo   +6 more
doaj   +1 more source

Genotipos frecuentemente asociados a trombofilias

open access: yesBiomédica: revista del Instituto Nacional de Salud, 2014
La enfermedad tromboembólica venosa es una entidad patológica importante debido a la morbilidad que causa, por sus complicaciones y por su alta incidencia en el mundo, la cual puede variar desde 1:100 en adultos mayores hasta 1:100.000 en niños.
Helena Hernández-Cuervo   +2 more
doaj   +1 more source

Índice predictivo para la estratificación del riesgo de enfermedad tromboembólica venosa en pacientes con hemopatías malignas

open access: yesActa Médica del Centro, 2021
Introducción: la enfermedad tromboembólica venosa es una frecuente complicación en las hemopatías malignas y tiene un significativo impacto en la morbilidad y la mortalidad.
Agnerys López Sacerio   +4 more
doaj  

Home - About - Disclaimer - Privacy